Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52(3):197–205.
Article
Google Scholar
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–73.
Article
CAS
Google Scholar
Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014;20(7):1149–55.
Article
Google Scholar
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813–21.
Article
Google Scholar
Fortun J, Carratala J, Gavalda J, Lizasoain M, Salavert M, de la Camara R, Borges M, Cervera C, Garnacho J, Lassaleta A, et al. Guidelines for the treatment of invasive fungal disease by aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 update. Enferm Infecc Microbiol Clin. 2011;29(6):435–54.
Article
Google Scholar
Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20(121):156–74.
Article
CAS
Google Scholar
Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26.
Article
CAS
Google Scholar
Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL, European conference on infections in L. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European conference on infections in leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.
Article
CAS
Google Scholar
Klingspor L, Saaedi B, Ljungman P, Szakos A. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009). Mycoses. 2015;58(8):470–7.
Article
Google Scholar
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.
Article
Google Scholar
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.
Article
CAS
Google Scholar
Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37.
Article
CAS
Google Scholar
FDA Anti-infective Drugs Advisory Committee. Advisory Committee Briefing Document. Isavuconazonium: Invasive Aspergillosis and Invasive Mucormycosis [https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2015/January/12015%20AIDACB101FDA_Backgrounder.pdf]. Accessed 17 Jan 2019.
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.
Article
Google Scholar
Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Florl C, Calandra T, Viscoli C, Herbrecht R. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–44.
Article
Google Scholar
Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J. Cost-effectiveness analysis of Isavuconazole vs. Voriconazole as first-line treatment for invasive aspergillosis. Adv Ther. 2017;34(1):207–20.
Article
Google Scholar
Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78(6):532–9.
Article
CAS
Google Scholar
European Medicines Agency. Summary of Product Characteristcs. VFEND 50 mg and 200 mg film-coated tablets, VFEND 200 mg powder for solution for infusion, VFEND 200 mg powder and solvent for solution for infusion, VFEND 40 mg/ml powder for oral suspension. [https://www.medicines.org.uk/emc/product/7977]. Accessed 17 Jan 2019.
European Medicines Agency. Summary of Product Characteristics: Cresemba 100 mg hard capsules. https://www.medicines.org.uk/emc/product/5071. Accessed 17 Jan 2019.
European Medicines Agency. Summary of Product Characteristics: Cresemba 200 mg powder for concentrate for solution for infusion. https://www.medicines.org.uk/emc/product/5069. Accessed 17 Jan 2019.
Bagshaw E, Kuessner D, Posthumus J, Escrig C, Blackney M, Heimann SM, Cornely OA. The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK. Future Microbiol. 2017;12:515–25.
Article
CAS
Google Scholar
Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, Franks B, Shorr AF. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19(7):728–34.
Article
Google Scholar
Xhaard A, Lanternier F, Porcher R, Dannaoui E, Bergeron A, Clement L, Lacroix C, Herbrecht R, Legrand F, Mohty M, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French multicentre cohort study (2003-2008). Clin Microbiol Infect. 2012;18(10):E396–400.
Article
CAS
Google Scholar
European Medicines Agency. Summary of Product Characteristics: AmBisome® 50 mg powder for solution for infusion (liposomal amphotericin B). https://www.medicines.org.uk/emc/medicine/1236. Accessed 17 Jan 2019.
European Medicines Agency. Summary of Product Characteristics: Noxafil 100 mg Gastro-resistant Tablets. https://www.medicines.org.uk/emc/product/5388/smpc. Accessed 17 Jan 2019.
Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103(1):205–12.
Article
CAS
Google Scholar
Tandvårds- och läkemedelsförmånsverket: TLV price list https://www.tlv.se/. Accessed 17 Jan 2019.
Apoteket [http://www.apoteket.se]. Accessed 17 Jan 2019.
Region Skåne. Price list. Inpatient daily cost at haematology clinic. Code: VD010. 2015 [http://sodrasjukvardsregionen.se/download/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2015/].
Google Scholar
Ament AJ, Hubben MW, Verweij PE, de Groot R, Warris A, Donnelly JP, Van ‘t Wout J, Severens JL. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother. 2007;60(2):385–93.
Article
CAS
Google Scholar
Stam WB, O’Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008;81(6):467–74.
Article
Google Scholar
Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391–402.
Article
CAS
Google Scholar
Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014;93(3):198–206.
Article
Google Scholar
Bower H, Andersson TM, Bjorkholm M, Dickman PW, Lambert PC, Derolf AR. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6:e390.
Article
CAS
Google Scholar
Svensson M, Nilsson FO, Arnberg K. Reimbursement decisions for Pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229–36.
Article
Google Scholar
Adkins EM, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? Clinicoecon Outcomes Res. 2017;9:327–42.
Article
Google Scholar
Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–67.
Article
CAS
Google Scholar
Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (prospective antifungal therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293–300.
Article
Google Scholar
Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.
Article
Google Scholar
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–100.
Article
Google Scholar
Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.
PubMed
Google Scholar
Montagna MT, Lovero G, Coretti C, Martinelli D, Delia M, De Giglio O, Caira M, Puntillo F, D’Antonio D, Venditti M, et al. SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. Infection. 2014;42(1):141–51.
Article
CAS
Google Scholar
Bagshaw E, Enoch D, Micallef-Eynaud P, Blackney M, Posthumus P, Longshae C, Kuessner D. The cost of treating invasive mould disease caused by aspergillus and other filamentous fungi with isavuconazole compared with liposomal amphotericin B followed by posaconazole in the United Kingdom. Vienna: Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases; 2017. p. P1740.
Google Scholar
Bagshaw E, Blackney M, Heimann SM, Escrig C, Posthumus J, Kuessner D, Cornely OA. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Germany: economic evaluation of the phase III VITAL study and FungiScope matched case-control analysis. Vienna: Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases; 2017. p. EP0396.
Google Scholar
Bagshaw E, Carotti A, Blackney M, Chiarini V, Posthumus J, Kuessner D. The cost of treating mucormycosis with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Italy: economic evaluation of the phase III vital study and Fungiscope™ matched case-control analysis. Marseille: Presented at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation; 2017. p. A352.
Google Scholar
Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, Kowalski D, Lademacher C, Lewis W, Pearlman H, et al. Pharmacokinetic assessment of drug-drug interactions of Isavuconazole with the Immunosuppressants cyclosporine, mycophenolic acid, prednisolone, Sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85.
Article
CAS
Google Scholar